SCHEMBL2260308

SCHEMBL2260308

Cc1ccc(Cn2c(-c3ccc(Oc4ccccc4)cc3)cc(C(F)(F)C(F)(F)F)c(C#N)c2=O)c(C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.63
NR1H2 P55055 3/20 0.63
NR1H3 Q13133 3/20 0.63
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 6/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 2/20 0.38
PPARG P37231 1/20 0.38
NCOA2 Q15596 1/20 0.38
NCOA1 Q15788 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
MGAT2 Q10469 1/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
GRM2 Q14416 2/20 0.36
PDE9A O76083 1/20 0.35
PDE1C Q14123 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2262462 0.92 RXRA (0.63) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2261874 0.92 RXRA (0.50) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL12389419 0.90 RXRA (0.62) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2263400 0.90 NR1H2 (0.69) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2261462 0.88 RXRA (0.58) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2262536 0.88 NR1H2 (0.66) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2266726 0.88 NR1H2 (0.65) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2263683 0.88 NR1H2 (0.65) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2263662 0.87 RXRA (0.62) RXRANR1H2NR1H3MAPTPPARG
SCHEMBL2265524 0.86 RXRA (0.56) RXRANR1H2NR1H3ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS, INC. 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors NR1H2, NR1H3, NCOA1 RXRA 16/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.